These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Half-time photodynamic therapy for central serous chorioretinopathy. Tsai MJ; Hsieh YT Optom Vis Sci; 2014 Sep; 91(9):1140-5. PubMed ID: 25083838 [TBL] [Abstract][Full Text] [Related]
23. Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy. Chung CY; Chan YY; Li KKW Ophthalmologica; 2018; 240(1):37-44. PubMed ID: 29566395 [TBL] [Abstract][Full Text] [Related]
24. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea. van Dijk EHC; Dijkman G; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835 [TBL] [Abstract][Full Text] [Related]
25. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy. Kim YK; Ryoo NK; Woo SJ; Park KH Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728 [TBL] [Abstract][Full Text] [Related]
26. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089 [TBL] [Abstract][Full Text] [Related]
27. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis). Lai TY; Wong RL; Chan WM Trans Am Ophthalmol Soc; 2015; 113():T8. PubMed ID: 26755855 [TBL] [Abstract][Full Text] [Related]
28. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF; Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758 [TBL] [Abstract][Full Text] [Related]
29. One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy. Pichai J; Vanchalerm B; Mansing R BMC Ophthalmol; 2021 Jan; 21(1):30. PubMed ID: 33430812 [TBL] [Abstract][Full Text] [Related]
30. Long term outer retinal changes in central serous chorioretinopathy submitted to half-dose photodynamic therapy. Torres-Costa S; Penas S; Cerqueira AR; Brandão E; Carneiro Â; Rocha-Sousa A; Falcão-Reis F Photodiagnosis Photodyn Ther; 2021 Jun; 34():102235. PubMed ID: 33631379 [TBL] [Abstract][Full Text] [Related]
31. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Nicolò M; Zoli D; Musolino M; Traverso CE Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224 [TBL] [Abstract][Full Text] [Related]
32. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy. Russo A; Turano R; Morescalchi F; Gambicorti E; Cancarini A; Duse S; Costagliola C; Semeraro F Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1141-1148. PubMed ID: 28283732 [TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230 [TBL] [Abstract][Full Text] [Related]
34. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551 [TBL] [Abstract][Full Text] [Related]
35. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Noh SR; Kang MS; Kim K; Kim ES; Yu SY Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247 [TBL] [Abstract][Full Text] [Related]
36. The one-year results of half-dose photodynamic therapy with verteporfin in chronic or recurrent central serous chorioretinopathy. Jirarattanasopa P; Ratanasukon M; Bhurayanontachai P J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S56-60. PubMed ID: 22696853 [TBL] [Abstract][Full Text] [Related]
37. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy. van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176 [TBL] [Abstract][Full Text] [Related]
38. Early visual and morphologic changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Alkin Z; Ozkaya A; Agca A; Yazici AT; Demirok A J Ocul Pharmacol Ther; 2014 May; 30(4):359-65. PubMed ID: 24456481 [TBL] [Abstract][Full Text] [Related]
39. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results. Demircan A; Yesilkaya C; Alkin Z Photodiagnosis Photodyn Ther; 2018 Mar; 21():375-378. PubMed ID: 29409857 [TBL] [Abstract][Full Text] [Related]
40. Photodynamic therapy for steroid-associated central serous chorioretinopathy. Lee TG; Kim JE Br J Ophthalmol; 2011 Apr; 95(4):518-23. PubMed ID: 20679080 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]